Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

Related Articles by Review for PubMed (Select 16452684)

1.

A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons.

Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM.

J Neurosci. 2006 Feb 1;26(5):1604-15.

2.

Opiate physical dependence and N-methyl-D-aspartate receptors.

Noda Y, Nabeshima T.

Eur J Pharmacol. 2004 Oct 1;500(1-3):121-8. Review.

PMID:
15464026
3.

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

Behrens MM, Sejnowski TJ.

Neuropharmacology. 2009 Sep;57(3):193-200. doi: 10.1016/j.neuropharm.2009.06.002. Epub 2009 Jun 11. Review.

4.

Ethanol sensitivity of NMDA receptors.

Allgaier C.

Neurochem Int. 2002 Dec;41(6):377-82. Review.

PMID:
12213224
5.

Parvalbumin-containing interneurons in rat hippocampus have an AMPA receptor profile suggestive of vulnerability to excitotoxicity.

Moga D, Hof PR, Vissavajjhala P, Moran TM, Morrison JH.

J Chem Neuroanat. 2002 May;23(4):249-53. Review.

PMID:
12048108
6.

Glutamate-based therapeutic approaches: NR2B receptor antagonists.

Gogas KR.

Curr Opin Pharmacol. 2006 Feb;6(1):68-74. Epub 2005 Dec 22. Review.

PMID:
16376149
7.

The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia.

Rotaru DC, Lewis DA, Gonzalez-Burgos G.

Rev Neurosci. 2012 Jan 9;23(1):97-109. doi: 10.1515/revneuro-2011-0059. Review.

8.

Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia.

Powell SB, Sejnowski TJ, Behrens MM.

Neuropharmacology. 2012 Mar;62(3):1322-31. doi: 10.1016/j.neuropharm.2011.01.049. Epub 2011 Feb 17. Review.

9.

NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.

Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC.

Ann N Y Acad Sci. 2003 Nov;1003:176-84. Review.

PMID:
14684445
10.

The NMDA receptor hypofunction model of psychosis.

Farber NB.

Ann N Y Acad Sci. 2003 Nov;1003:119-30. Review.

PMID:
14684440
11.
12.

Review of NMDA antagonist-induced neurotoxicity and implications for clinical development.

Low SJ, Roland CL.

Int J Clin Pharmacol Ther. 2004 Jan;42(1):1-14. Review.

PMID:
14756381
13.

NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Gonzalez-Burgos G, Lewis DA.

Schizophr Bull. 2012 Sep;38(5):950-7. doi: 10.1093/schbul/sbs010. Epub 2012 Feb 21. Review.

14.

Interneurons. Fast-spiking, parvalbuminâș GABAergic interneurons: from cellular design to microcircuit function.

Hu H, Gan J, Jonas P.

Science. 2014 Aug 1;345(6196):1255263. doi: 10.1126/science.1255263. Epub 2014 Jul 31. Review.

PMID:
25082707
15.

Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function.

Sanchez-Perez A, Llansola M, Cauli O, Felipo V.

Cerebellum. 2005;4(3):162-70. Review.

PMID:
16147948
16.

Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia.

Timofeeva OA, Levin ED.

Neuroscience. 2011 Nov 10;195:21-36. doi: 10.1016/j.neuroscience.2011.08.038. Epub 2011 Aug 22. Review.

PMID:
21884762
17.

GABAergic interneuron origin of schizophrenia pathophysiology.

Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, Belforte JE.

Neuropharmacology. 2012 Mar;62(3):1574-83. doi: 10.1016/j.neuropharm.2011.01.022. Epub 2011 Jan 26. Review.

18.

How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.

Wang X, Pinto-Duarte A, Sejnowski TJ, Behrens MM.

Antioxid Redox Signal. 2013 Apr 20;18(12):1444-62. doi: 10.1089/ars.2012.4907. Epub 2012 Oct 18. Review.

19.

The Yin and Yang of NMDA receptor signalling.

Hardingham GE, Bading H.

Trends Neurosci. 2003 Feb;26(2):81-9. Review.

PMID:
12536131
20.

Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Steullet P, Cabungcal JH, Monin A, Dwir D, O'Donnell P, Cuenod M, Do KQ.

Schizophr Res. 2014 Jul 4. pii: S0920-9964(14)00313-2. doi: 10.1016/j.schres.2014.06.021. [Epub ahead of print] Review.

PMID:
25000913
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk